Hemab Therapeutics Holdings Inc

{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ null, null, 1.93, 19.12, 107 ], "ebit_estimate": [ -106.44, -130.93, -163.52, -193.42, -138.04 ], "ebitda_estimate": [ -109.52, -137.96, -162.54, null, null ], "net_income_estimate": [ -97.67, -119.96, -154.29, -185.18, -132.87 ], "per_share_eps_estimate": [ -2.38, -2.49, -3.16, -3.79, -2.69 ], "eps_nri_estimate": [ -2.83, -2.5, -3.17, -3.8, -2.7 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null ], "pretax_income_estimate": [ -97.67, -119.96, -154.29, -185.18, -132.87 ], "operating_cash_flow_per_share_estimate": [ null, null, null, null, null ], "roa_estimate": [ null, null, null, null, null ], "roe_estimate": [ null, null, null, null, null ], "gross_margin_estimate": [ null, null, null, null, 85 ], "operating_cash_flow_estimate": [ null, null, null, null, null ], "pettm_estimate": [ 0, 0, 0, 0, 0 ], "long_term_growth_rate_mean": -8.35, "long_term_revenue_growth_rate_mean": "0.00", "future_per_share_eps_estimate_growth": -10.02, "future_eps_nri_estimate_growth": -8.35, "future_revenue_estimate_growth": null, "future_ebit_estimate_growth": -31.62, "future_ebitda_estimate_growth": -31.87, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": -32.97, "future_pretax_income_estimate_growth": -32.83, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": null }

{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712" ], "revenue_estimate": [ null, null, null, null, null, null, null ], "ebit_estimate": [ -26.02, -26.45, -30.95, -31.44, null, null, null ], "ebitda_estimate": [ -28.43, -26.43, -32.44, -31.4, null, null, null ], "net_income_estimate": [ -22.74, -23.92, -27.79, null, null, null, null ], "per_share_eps_estimate": [ -0.48, -0.5, -0.61, null, null, null, null ], "eps_nri_estimate": [ -0.74, -0.5, -0.6, -0.54, -0.63, -0.57, -0.66 ], "dividend_estimate": [ null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null, null, null ], "pretax_income_estimate": [ -22.74, -23.92, -27.79, null, null, null, null ], "operating_cash_flow_per_share_estimate": [ null, null, null, null, null, null, null ], "roa_estimate": [ null, null, null, null, null, null, null ], "roe_estimate": [ null, null, null, null, null, null, null ], "gross_margin_estimate": [ null, null, null, null, null, null, null ], "operating_cash_flow_estimate": [ null, null, null, null, null, null, null ], "pettm_estimate": [ 0, 0, 0, null, null, null, null ], "long_term_growth_rate_mean": -8.35, "long_term_revenue_growth_rate_mean": "0.00", "future_per_share_eps_estimate_growth": -10.02, "future_eps_nri_estimate_growth": -8.35, "future_revenue_estimate_growth": null, "future_ebit_estimate_growth": -31.62, "future_ebitda_estimate_growth": -31.87, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": -32.97, "future_pretax_income_estimate_growth": -32.83, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": null }